APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Trial details
- Registry ID
- NCT03745716
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716 | Aprea Therapeutics | Phase 3 | Completed | 2020-11-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |